作者
Wouter T Zandee, Tessa Brabander, Anela Blažević, Boen LR Kam, Jaap JM Teunissen, Richard A Feelders, Johannes Hofland, Wouter W De Herder
发表日期
2019/4
期刊
The Journal of Clinical Endocrinology & Metabolism
卷号
104
期号
4
页码范围
1336-1344
出版商
Endocrine Society
简介
Purpose
Peptide receptor radionuclide therapy (PRRT) with the radiolabeled somatostatin analogue [Lutetium-177-DOTA0-Tyr3]octreotate (177Lu-DOTATATE) is widely applied for inoperable metastatic small intestinal and nonfunctioning pancreatic neuroendocrine tumors (pNETs). The aim of this study is to describe the safety and efficacy of the treatment of functioning pNETs.
Methods
Patients were treated with up to four cycles of 177Lu-DOTATATE with an intended dose of 7.4 Gbq per cycle. Radiological (Response Evaluation Criteria in Solid Tumors 1.1), symptomatic, and biochemical response were analyzed retrospectively for all patients with a functioning pNET (insulinoma, gastrinoma, VIPoma, and glucagonoma) treated with 177Lu-DOTATATE. Quality of life (QOL) was assessed with the European Organization for Research and Treatment of Cancer Quality of Life …
学术搜索中的文章
WT Zandee, T Brabander, A Blažević, BLR Kam… - The Journal of Clinical Endocrinology & Metabolism, 2019